Branded Generics Market Outlook & Key Findings
- Branded generics market slated to witness a CAGR of over 8% between 2020 and 2030
- Oral formulation remains preferred, with 55% of revenue share; parenteral formulation expected to take the lead in the forecast period
- Asia Pacific Excluding Japan (APEJ) to emerge as the market leader due to substantial rate of adoption of branded generics by large-scale pharmacy chains in the emerging economies
- Covid-19 to act as a major restraint for the next few months as flagship manufacturers have been dependent on China for procuring intermediates needed to produce APIs
- Use of branded generics in diabetes and cardiovascular disease accounts for one-fifth of all market revenue
Branded Generics Market Revenue to Grow 2x by 2030
The generics industry is nearing consolidation, thanks to the growing rate of adoption by big manufacturers in US and EU, coupled with new launches and regulatory approvals.
Increasing affordability of branded generics will particularly create a favorable growth environment in developing regions.
This study forecasts that the global branded generics market revenue is likely to grow more than double by 2030. The current scenario is such that “Generic” names are more popular than the branded ones. For instance – “Amoxicillin” is a well-known drug to treat bacterial infections. However, it’s not “branded” by any means. The “branded” name is “Trimox”.
Parenteral Formulation to be Preferred over Conventional Formulations
Even though oral formulations account for more than half of the branded generics market revenue, the future belongs to “Parenteral Formulation”.
Towards the end of forecast period, adoption of parenteral formulation would witness a robust CAGR, accounting for over a quarter of the total market value projected for 2030.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Anti-Hypertensive Branded Generics Adoption Growing
Cardiac arrests, diabetes, and hypertension account for a significant percent of all fatalities around the globe. There has been an ever-increasing demand for anti-hypertensive drugs from all across. This calls for affordable drugs, and branded generics have proven to be a pragmatic solution.
Lipid-lowering Branded Generics to Gather Traction
Lipid-lowering branded generics demand is on the rise as obesity is rising at an exponential rate. As per CDC, the percentage of obese people in the U.S. alone has almost doubled in the last decade. The market players are looking forward to get on to lipid-lowering mode to facilitate weight loss. Generic Atorvastatin is one such lipid-lowering drug. Likewise, others will also be into fray in the forecast period.
Spearheaded by China and India, Asia Pacific (excluding Japan) will continue to lead global branded generics market and is poised for a steady CAGR through 2030.
North America and Western Europe hold a collective share of just-about 30%, which would most likely witness a dip towards the end of projection period as saturation is setting in.
Increasing adoption of branded generic drugs by large-scale pharmacy chains will remain a key factor pushing sales of branded generics in the near future. This trend will be prominent in the emerging economies, particularly India, Latin America, and China.
Currently, a majority of investments in the branded generics space are concentrated in selective developing markets that promise to deliver solid returns as compared to developed markets.
Notable expansion of the affluent consumer population and willingness to pay for prescription medicines are building up the market attractiveness of Asia, Latin America, and Africa.
Branded Generics Market Competitive Landscape
Conducive regulatory environment in developing markets such as India and China is fuelling growth of contract manufacturing organizations engaged in manufacturing of branded generics.
India currently has a repository of 60,000 generic brands across 60 therapeutic categories and is home to manufacturers of more than 500 APIs. Reduced approval time for new facilities to start operations will boost investments in setting up of facilities.
Global market for branded generics has been a fairly fragmented landscape in terms of competition. While Mylan, Pfizer, Teva, and Abbott represent some of the top players, the commercial success of market majorly relies on distribution oriented mergers, acquisitions, and join ventures.
The Way Forward
Global branded generics market is poised for a steady CAGR during 2020 – 2030. However, the market will take some time to pick up as of now, as the outbreak of Covid-19 has compelled the manufacturers to revisit the supply chain.
When it comes to APIs, relying on China can’t be ruled out. This has resulted in an uncertainty in terms of production and delivery. For everything – right from availability of raw material to time diverted to research; post-Covid-19 plans need to be chalked out.
Once the stability sets in (say – after a few months from now), the market will be geared up for research on branded generics for Covid-19 as well as the other illnesses that have been costing patients a fortune.
BRANDED GENERICS MARKET TAXONOMY
The global branded generics is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Cardiovascular Diseases
- Gastrointestinal Diseases
- Dermatology Diseases
- Analgesics and Anti-inflammatory
- Alkylating Agents
- Lipid Lowering Drugs
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
- North America
- Latin America
- Western Europe
- Eastern Europe